The British Liver Trust today warned the disease has become one of the fastest causes of cancer death in the UK, with over 5,400 people dying from it every year.
Sixteen people are diagnosed with liver cancer every day and most of the cases are linked to alcohol, obesity and hepatitis infection.
Cirrhosis, diabetes and smoking can also further increase the risk.
But liver cancer can be hard to spot, with many people showing no signs or symptoms in the early stages – when survival odds are best.
Oncimmune plc (LON:ONC) is a leader in the development, manufacture and marketing of personalised immunodiagnostics for the screening, detection and care of cancer. The Group has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company’s first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 156,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK, Europe & Asia. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT®-Liver launched in May 2018 and further tests are in development.
